Trial Profile
A Phase III, Observer-Blind, Randomized, Multi-Center Study to Evaluate Safety, Tolerability and Immunogenicity (in a Subset) Following a Single Intramuscular Dose of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs, in Healthy Adult and Elderly Subjects Who Received Either One or the Other Vaccine One Year Before [EXTENSION OF 700016836]
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Influenza vaccine (Optaflu) (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Chiron Corporation
- 01 Mar 2013 New trial record